Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Below 200-Day Moving Average - Here's Why

Key Points

• Northwest Biotherapeutics stock has fallen below its 200-day moving average of $0.26, closing at $0.25 with significant trading volume of 3,630,886 shares.
• The company reported a net loss of $0.01 per share and revenues of $0.13 million for the last quarter.
• Northwest Biotherapeutics specializes in developing personalized immune therapies for cancer using its DCVax technology platform.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.26 and traded as low as $0.25. Northwest Biotherapeutics shares last traded at $0.25, with a volume of 3,630,886 shares traded.

Northwest Biotherapeutics Trading Down 1.2%

The company has a fifty day moving average price of $0.25 and a two-hundred day moving average price of $0.26. The company has a market cap of $376.57 million, a price-to-earnings ratio of -4.15 and a beta of -1.14.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $0.13 million during the quarter.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.